

Supplement Table 1. Demographic and clinical characteristics of multiple sclerosis patients at baseline and follow-up, according to sex.

Demographic and clinical variables	Female (n=146)	Male (n=57)	p value
Time in months between baseline and follow-up, mean (SD)	56.7 (34.2)	51.9 (30.7)	0.352
Number of gadodiamide administrations between baseline and follow-up, mean (SD) median (IQR)	9.4 (5.6) 8.5 (5-13)	8.8 (5.4) 7 (5-12.5)	0.622
Age at onset, mean (SD)	34 (12.1)	30.1 (8.3)	0.084
Age in years at the follow-up, mean (SD)	43.6 (12.6)	40.2 (9.7)	0.067
Disease duration in years at baseline, mean (SD)	0.9 (0.4)	0.8 (0.4)	0.145
Disease duration in years the follow-up, mean (SD)	4.7 (2.8)	4.3 (2.6)	0.352
Disease course at baseline, n (%)			
Clinically isolated syndrome	50 (34.3)	21 (36.8)	0.745
Relapsing-remitting	96 (55.7)	36 (53.2)	
Disease course at the follow-up, n (%)			
Clinically isolated syndrome	0 (0)	0 (0)	0.999
Relapsing-remitting	146 (100)	57 (100)	
Expanded Disability Status Scale at baseline, median (IQR)	2.0 (1.5-3.0)	2.0 (1.5-3.4)	0.877
Expanded Disability Status Scale at the follow-up, median (IQR)	2.5 (1.5-3.5)	2.0 (1.5-3.5)	0.692
Number of relapses between baseline and follow-up, mean (SD)	2.7 (0.8)	2.7 (0.8)	0.887
SIR of DN to pons at follow-up, mean (SD)	1.051 (0.05)	1.067 (0.05)	0.007
SIR of DN to CSF-LVV at follow-up, mean (SD)	2.667 (0.41)	2.769 (0.41)	0.027
DN T1 hyperintensity, n (%)			
Present	69 (47.3)	31 (54.4)	0.435
Absent	77 (52.7)	26 (43.6)	
SIR of GP to pons at follow-up, mean (SD)	1.052 (0.07)	1.035 (0.06)	0.08
SIR of GP to CSF-LVV at follow-up, mean (SD)	2.663 (0.46)	2.681 (0.43)	0.791
SIR of thalamus to pons at follow-up, mean (SD)	0.962 (0.06)	0.941 (0.06)	0.126
SIR of thalamus to CSF-LVV at follow-up, mean (SD)	2.431 (0.36)	2.432 (0.31)	0.956
Disease modifying therapy at the follow-up, n (%)			
Interferon beta-1a I.M.	45 (30.8)	13 (22.8)	0.423
Interferon beta-1a S.C.	14 (9.6)	5 (8.8)	
Glatiramer acetate	26 (17.8)	13 (22.8)	
Natalizumab	15 (10.3)	5 (8.8)	
Dimethyl-fumarate	13 (8.9)	8 (14)	
Fingolimod	3 (2.1)	2 (3.5)	
Teriflunomide	2 (1.1)	1 (1.8)	
Other therapies	17 (11.6)	6 (10.5)	
No therapy	9 (6.2)	4 (7)	

Legend: MS-multiple sclerosis; RR-relapsing-remitting; IQR-interquartile range; SD-standard deviation; I.M.-intramuscular; S.C.-subcutaneous; NA-non available; SIR-signal intensity ratio; DN-dentate nucleus; GP-globus pallidus.

Other therapies include combined therapies and steroids.

p values represent differences between the MS female and male groups. The differences between the groups were analyzed using chi square, Mann-Whitney-rank sum test or Student's t-test for demographic and clinical measures, whereas the SIR differences between the groups were analyzed using analysis of covariance, adjusted for age and volume of region of interest. In bold are shown p values <0.05.